Hikma Pharmaceuticals (HIK)

 

HIK Share PerformanceMore

52 week high2,346.0 16/03/17
52 week low1,101.0 17/08/17
52 week change -815.0 (-40.75%)
4 week volume13,902,773 22/09/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut it...

Block listing Interim Review

RNS Number: 8014S Hikma Pharmaceuticals Plc 05 October 2017 Block Listing Six Monthly Return Information provided on this form must be typed or printed electronically and provided to an RIS. Date: 5 October 2017 Name of applicant: Hikma Pharmaceuticals PLC Name of scheme: Hikma Pharmaceuticals PLC 2004 Stock Option Plan (" SOP ") & Hikma Pharm...

Total Voting Rights

RNS Number: 4598S Hikma Pharmaceuticals Plc 02 October 2017 Hikma Pharmaceuticals PLC Total Voting Rights and Capital LONDON, 2 October 2017 - In accordance with the UK Financial Conduct Authority's (the " FCA ") DTR 5.6.1, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 30 Se...

Holding(s) in Company

RNS Number: 1448S Hikma Pharmaceuticals Plc 28 September 2017 TR-1: S tandard form for notification of major holdings LONDON, 28 September 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75) , the fast-growing multinational pharmaceuticals group, announces as follows: NOTIFICATION OF MAJOR HOL...

Holding(s) in Company

RNS Number: 7141R Hikma Pharmaceuticals Plc 25 September 2017 TR-1: S tandard form for notification of major holdings LONDON, 25 September 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75) , the fast-growing multinational pharmaceuticals group, announces as follows: NOTIFICATION OF MAJOR HOL...

Holding(s) in Company

RNS Number: 8069Q Hikma Pharmaceuticals Plc 14 September 2017 TR-1: S tandard form for notification of major holdings LONDON, 14 September 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75) , the fast-growing multinational pharmaceuticals group, announces as follows: NOTIFICATION OF MAJOR HOL...

Broker Forecast - Cantor Fitzgerald issues a broker note on Hikma Pharmaceuticals PLC

Cantor Fitzgerald today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price ...

Broker Forecast - Stifel issues a broker note on Hikma Pharmaceuticals PLC

Stifel today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to hold (from buy) and cut its p...

Fundamental DataMore

P/E ratio17.82
EPS66.5
Dividend yield2.785 %

Latest discussion posts More

  • Wake up everyone - perspective!

    Hello all. Let's not forget this business earns around two thirds of it's profit from injectables. Much too large a portion to be caught up in the generics downturn to the ...
    24-Aug-2017
    middler2
  • Re: raising prices

    Yes they can charge what they like, BUT the healthcare insurance companies can direct that a much cheaper alternative is used/supplied. The price hike strategy can backfire ...
    22-Aug-2017
    Proverbs 26 vs 5
  • raising prices

    Are they allowed to raise prices 430% This seems excessive.
    21-Aug-2017
    susanne9

Users' HoldingsMore

Users who hold Hikma Pharmaceuticals also hold..
LLOYDS GRP.37%
GLAXOSMITHKLINE29%
BP24%
RDS 'B'24%
BT GROUP24%

Codes & Symbols

ISINGB00B0LCW083
SymbolsHIK, LSE:HIK, HIK.L, HIK:LN, LON:HIK, XLON:HIK